Phase I Study of Chiauranib in Patients With Advanced Solid Tumors
The purpose of this dose-escalation study is to assess the safety and tolerability of treatment with Chiauranib administered orally over a range of doses in patients with advanced solid tumors.
Solid Tumors
DRUG: Chiauranib
dose-limiting toxicity (DLT), day 1-28|Number of Adverse Events, An expected average of 8 months
pharmacokinetic profile of Chiauranib, On day 1,8,15,22,25,26,27,28|Evidence of benefit, clinical benefit rate (complete response (CR),partial response (PR),stable disease (SD) \> 8 weeks),duration of response (DOR),time to progression (TTP), or tumor marker improvement, if appropriate, An expected average of 8 months|Pharmacodynamic profile of Chiauranib, Plasma biomarkers: soluble vascular endothelial growth factor receptors (sVEGFR2), vascular endothelial growth factor (VEGF) Tumor tissue biomarkers: Aurora B, phospho-histone H3, On day 15,28
The purpose of this study is to assess the tolerability and safety include adverse events, vital signs, laboratory tests ,etc., of a range of doses of Chiauranib in solid tumor patients, and to determine the dose limit toxicity and the maximum tolerable dose.